Journey Medical Corp (DERM) Stock Forecast & Price Target
Journey Medical Corp · NASDAQ
$6.36+0.17 (+2.75%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Journey Medical Corp, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $12.00 to $13.00, so the covering firms are broadly aligned. The average target of $12.67 sits 99% above the current $6.36. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.05 next quarter toward $1.04 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Journey Medical Corp.
As of Jul, 2 of 2 firms rate DERM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DERM EPS & revenue forecast
EPS · NEXT QUARTER
$0.05
Range $0.01 – $0.14 · 4 analysts · -158% YoY
Next period, 4 analysts expect Journey Medical Corp to earn $0.05 a share (range $0.01 – $0.14), versus $-0.09 a year earlier. Full-year consensus is $0.07, growing to $1.04 the year after.
REVENUE · NEXT QUARTER
$22.4M
Range $21.9M – $23.4M · 4 analysts · +27% YoY
Revenue is expected to reach $22.4M (range $21.9M – $23.4M), +27.0% year-over-year. Full-year consensus is $82.6M, rising to $137.7M next year.
Top analysts covering Journey Medical Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DERM.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$12.00+88.7% to target
Overall win rate
53%
+ Follow
#2
BF
Brandon Folkes
HC Wainwright & Co.
Buy
$13.00+104.4% to target
Coverage
—
+ Follow
#3
TF
Thomas Flaten
Lake Street
Buy
$13.00+104.4% to target
Coverage
—
+ Follow
#4
KP
Kalpit Patel
B. Riley Securities
Buy
$12.00+88.7% to target
Coverage
—
+ Follow
DERM stock forecast FAQ
What is DERM's average 12-month price target?+
The 3 analysts with a live target average $12.67 for Journey Medical Corp over the next 12 months, ranging from a $13.00 high to a $12.00 low.
Is DERM stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DERM?+
The Street-high target is $13.00 (HC Wainwright & Co.), and the Street-low is $12.00 (B. Riley Securities). The average of all 3 active targets is $12.67.
How many Wall Street analysts cover DERM?+
3 analysts have an active rating on Journey Medical Corp, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering DERM?+
Among analysts who currently cover DERM, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $12.00 target.
What is Journey Medical Corp's projected EPS for next quarter?+
The consensus estimate is $0.05 per share (range $0.01 – $0.14) across 4 analysts. Full-year EPS is projected at $0.07, rising to $1.04 the following year.
How much revenue is Journey Medical Corp expected to report next quarter?+
Consensus revenue is $22.4M (range $21.9M – $23.4M). Full-year revenue is projected at $82.6M, growing to $137.7M next year.
Have analysts been upgrading or downgrading DERM lately?+
As of Jul, 2 of 2 firms rate DERM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DERM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
